Metformin's Effects on ALS in Mice
Author Information
Author(s): Kaneb Hannah M., Sharp Paul S., Rahmani-Kondori Nazanin, Wells Dominic J.
Primary Institution: Imperial College, Royal Veterinary College, Sheffield University
Hypothesis
Metformin might increase survival in the SOD1G93A murine model of ALS.
Conclusion
Metformin is not beneficial for ALS and may be harmful in female mice.
Supporting Evidence
- Metformin treatment did not improve survival in male or female SOD1G93A mice.
- In female mice, higher doses of metformin were associated with faster disease progression.
- Initial studies showed some motor unit survival benefits, but these did not translate to long-term outcomes.
Takeaway
Researchers tested a diabetes drug called metformin on mice with ALS, but it didn't help and might have made things worse for female mice.
Methodology
Mice were treated with different doses of metformin, and their motor unit survival, disease onset, and progression were monitored.
Potential Biases
Potential biases from gender differences in disease progression and treatment effects.
Limitations
The study may not fully account for all variables affecting ALS progression and treatment response.
Participant Demographics
SOD1G93A mice, both male and female.
Statistical Information
P-Value
p<0.005 for motor unit survival in males, p=0.0134 for females.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website